These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 19262672)

  • 1. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens.
    Brinster S; Lamberet G; Staels B; Trieu-Cuot P; Gruss A; Poyart C
    Nature; 2009 Mar; 458(7234):83-6. PubMed ID: 19262672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug discovery: Not as fab as we thought.
    Zlitni S; Brown ED
    Nature; 2009 Mar; 458(7234):39-40. PubMed ID: 19262660
    [No Abstract]   [Full Text] [Related]  

  • 3. Type II Fatty Acid Synthesis Pathway and Cyclopropane Ring Formation Are Dispensable during Enterococcus faecalis Systemic Infection.
    Hays C; Lambert C; Brinster S; Lamberet G; du Merle L; Gloux K; Gruss A; Poyart C; Fouet A
    J Bacteriol; 2021 Sep; 203(20):e0022121. PubMed ID: 34309397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Staphylococcus aureus FASII bypass escape route from FASII inhibitors.
    Morvan C; Halpern D; Kénanian G; Pathania A; Anba-Mondoloni J; Lamberet G; Gruss A; Gloux K
    Biochimie; 2017 Oct; 141():40-46. PubMed ID: 28728970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essentiality of FASII pathway for Staphylococcus aureus.
    Balemans W; Lounis N; Gilissen R; Guillemont J; Simmen K; Andries K; Koul A
    Nature; 2010 Jan; 463(7279):E3; discussion E4. PubMed ID: 20090698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics.
    Yao J; Rock CO
    J Biol Chem; 2015 Mar; 290(10):5940-6. PubMed ID: 25648887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staphylococcus aureus Utilizes Host-Derived Lipoprotein Particles as Sources of Fatty Acids.
    Delekta PC; Shook JC; Lydic TA; Mulks MH; Hammer ND
    J Bacteriol; 2018 Jun; 200(11):. PubMed ID: 29581406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials.
    Morvan C; Halpern D; Kénanian G; Hays C; Anba-Mondoloni J; Brinster S; Kennedy S; Trieu-Cuot P; Poyart C; Lamberet G; Gloux K; Gruss A
    Nat Commun; 2016 Oct; 7():12944. PubMed ID: 27703138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus.
    Gloux K; Guillemet M; Soler C; Morvan C; Halpern D; Pourcel C; Vu Thien H; Lamberet G; Gruss A
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permissive Fatty Acid Incorporation Promotes Staphylococcal Adaptation to FASII Antibiotics in Host Environments.
    Kénanian G; Morvan C; Weckel A; Pathania A; Anba-Mondoloni J; Halpern D; Gaillard M; Solgadi A; Dupont L; Henry C; Poyart C; Fouet A; Lamberet G; Gloux K; Gruss A
    Cell Rep; 2019 Dec; 29(12):3974-3982.e4. PubMed ID: 31851927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (p)ppGpp/GTP and Malonyl-CoA Modulate Staphylococcus aureus Adaptation to FASII Antibiotics and Provide a Basis for Synergistic Bi-Therapy.
    Pathania A; Anba-Mondoloni J; Gominet M; Halpern D; Dairou J; Dupont L; Lamberet G; Trieu-Cuot P; Gloux K; Gruss A
    mBio; 2021 Feb; 12(1):. PubMed ID: 33531402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exogenous fatty acid metabolism in bacteria.
    Yao J; Rock CO
    Biochimie; 2017 Oct; 141():30-39. PubMed ID: 28668270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutathione Synthesis Contributes to Virulence of
    Walker EA; Port GC; Caparon MG; Janowiak BE
    J Bacteriol; 2019 Oct; 201(20):. PubMed ID: 31331978
    [No Abstract]   [Full Text] [Related]  

  • 14. Mining Fatty Acid Biosynthesis for New Antimicrobials.
    Radka CD; Rock CO
    Annu Rev Microbiol; 2022 Sep; 76():281-304. PubMed ID: 35650664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of selectivity and efficacy of fatty acid synthesis inhibitors.
    Kodali S; Galgoci A; Young K; Painter R; Silver LL; Herath KB; Singh SB; Cully D; Barrett JF; Schmatz D; Wang J
    J Biol Chem; 2005 Jan; 280(2):1669-77. PubMed ID: 15516341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.
    Parsons JB; Frank MW; Subramanian C; Saenkham P; Rock CO
    Proc Natl Acad Sci U S A; 2011 Sep; 108(37):15378-83. PubMed ID: 21876172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bactericidal Fatty Acid Mimetic 2CCA-1 Selectively Targets Pneumococcal Extracellular Polyunsaturated Fatty Acid Metabolism.
    Reithuber E; Nannapaneni P; Rzhepishevska O; Lindgren AEG; Ilchenko O; Normark S; Almqvist F; Henriques-Normark B; Mellroth P
    mBio; 2020 Dec; 11(6):. PubMed ID: 33323510
    [No Abstract]   [Full Text] [Related]  

  • 18. Phenotypic antimicrobial susceptibility and occurrence of selected resistance genes in gram-positive mastitis pathogens isolated from Wisconsin dairy cows.
    Ruegg PL; Oliveira L; Jin W; Okwumabua O
    J Dairy Sci; 2015 Jul; 98(7):4521-34. PubMed ID: 25912858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acyl-AcpB, a FabT corepressor in
    Lambert C; d'Orfani A; Gaillard M; Zhang Q; Gloux K; Poyart C; Fouet A
    J Bacteriol; 2023 Oct; 205(10):e0027423. PubMed ID: 37811985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
    Jansen WT; Verel A; Verhoef J; Milatovic D
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3420-4. PubMed ID: 17606689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.